News & Updates
Showing Oncology articles
Showing

OS benefit of adjuvant osimertinib in resected EGFR-mutated NSCLC persists at 8th year
Adjuvant osimertinib continues to demonstrate an overall survival (OS) benefit over placebo in patients with resected EGFR-mutated (exon 19 del/L858R) non-small cell lung cancer (NSCLC), according to the 8-year exploratory analysis of the phase III ADAURA trial presented at WCLC 2026.

Tarlatamab – a new SoC in 2L SCLC
After decades of topotecan being the sole standard second-line (2L) treatment for small-cell lung cancer (SCLC) in most countries, tarlatamab’s efficacy and a favourable safety and tolerability profile vs chemotherapy (CT) have defined a new standard of care (SoC) for patients whose disease progressed on or after initial platinum-based CT, according to Dr Martin Wermke of the National Center for Tumor Diseases Dresden Early Clinical Trial Unit in Dresden, Germany, who spoke at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC).

Quadruple regimen shows promise as first-line treatment for extrapulmonary NEC
First-line treatment with surufatinib combined with serplulimab and etoposide/cisplatin (EP) regimen exhibits antitumour activity with manageable safety in patients with advanced or metastatic extrapulmonary neuroendocrine carcinoma (NEC), reports a study presented at ESMO Congress 2026.

ES-SCLC treatment shifts towards double maintenance after 1L
In a clinical exchange session at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC), Dr Junko Tanizaki of the Department of Medical Oncology, Kindai University Faculty of Medicine, Sakai City, Osaka, Japan, discussed current first-line (1L) standards and evolving practice in extensive-stage small-cell lung cancer (ES-SCLC), highlighting a shift towards using two agents as maintenance following 1L chemo-immunotherapy (chemo-IO).

Neoadjuvant T-DXd achieves modest pCR in HER2-low, HR-positive early-stage breast cancer
Neoadjuvant treatment with the HER2-directed antibody drug conjugate trastuzumab deruxtecan-nxki (T-DXd), whether alone or with endocrine therapy or chemotherapy, results in low pathologic complete response (pCR) rates in patients with HER2-low, hormone receptor (HR)-positive early-stage breast cancer, as shown in the TALENT trial.

Personalized mRNA cancer vaccine + pembrolizumab hits targets in phase III melanoma trial
In the large phase III INTerpath-001 study evaluating individuals with resected stage IIB–IV melanoma, recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) improved when the mRNA-based individualized neoantigen therapy intismeran autogene was added to pembrolizumab compared with pembrolizumab alone.


